Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20651457 | 0.80 | CLK4 (0.48) | MEN1KMT2APOLBCLK4SNCA | |
| SCHEMBL21061505 | 0.78 | SNCA (0.42) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL27201465 | 0.78 | MEN1 (0.53) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL14702065 | 0.77 | SNCA (0.45) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL21348027 | 0.75 | NPC1 (0.56) | MEN1KMT2ACLK4SNCANPC1 | |
| SCHEMBL1530858 | 0.75 | PDGFRB (0.47) | MEN1KMT2ACLK4SNCANPC1 | |
| SCHEMBL509566 | 0.75 | EGFR (0.64) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL19383541 | 0.74 | THRB (0.39) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL2671809 | 0.74 | PPARA (0.54) | MEN1KMT2AEGFRPOLBNR2F2 | |
| SCHEMBL31473778 | 0.74 | WNT3A (0.62) | MEN1KMT2AEGFRPOLBNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | MEN1 2285/4885KMT2A 1959/4885EGFR 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.